设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 312|回复: 0

56届美国血液学年会报告,圣弗朗西斯科,2014年12月4日-9日

[复制链接]
发表于 2015-11-22 22:38:44 | 显示全部楼层 |阅读模式
Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014
Abstract
The 56th annual ASH (American Society of Haematology) meeting was held in San Francisco (CA). More than 3,000 abstracts were selected for presentation due to the huge amount of information from basic science to clinical experience. The future direction in haematoncology is targeted therapies for most diseases; for instance, anti-PD-1 and CAR-T cells in lymphoproliferative disorders and novel immunomodulatory agents active in the contest of bone marrow milieu in multiple myeloma. On the other hand, in aggressive haematological diseases (AML, ALL), clinical studies demonstrated the feasibility of a more intensive chemotherapy approach in older patients.
Keywords: chimeric antigen receptors, intensive chemotherapy, PD-1 inhibitors, target therapy
56届美国血液学年会报告,圣弗朗西斯科,2014124-9
摘要:
56届美国血液协会年会在圣弗朗西斯科举办。由于从基础研究到临床试验需要大量的信息,所以会议上选择了超过3000篇摘要。未来的研究方向是靶向治疗这些肿瘤疾病:例如,抗PD-1CAR-T细胞治疗在淋巴组织增生性疾病上的应用,以及新型免疫调节剂在多发性骨髓瘤骨髓环境中的作用。另一方面,在侵袭性血液病(AMLALL),临床研究表明在老年患者中更密集的化疗方法的可行性。
关键词:嵌合抗原受体,密集的化疗,PD-1抑制剂,靶向治疗
出自爱康得

Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014 2015.11.22.pdf

344.45 KB, 下载次数: 179

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-1-17 10:52 , Processed in 0.103505 second(s), 27 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表